Avita Medical Reports Q2 2025 Financial Results
Key points
- RECELL System approved for thermal burn and trauma wound treatment in US
- Exclusive rights to manufacture, market, and distribute PermeaDerm and Cohealyx in US
- RECELL System approved in international markets for skin healing applications
Full summary
Avita Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, has filed its Form 10-Q for the quarter ended 30 June 2025. The company's RECELL System, approved by the FDA for the treatment of thermal burn and trauma wounds in the US, continues to be a key focus. Avita Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, in the US. In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
Summary generated by a large language model. Please interpret with care.